HRP20020693B1 - HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß - Google Patents

HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß

Info

Publication number
HRP20020693B1
HRP20020693B1 HR20020693A HRP20020693A HRP20020693B1 HR P20020693 B1 HRP20020693 B1 HR P20020693B1 HR 20020693 A HR20020693 A HR 20020693A HR P20020693 A HRP20020693 A HR P20020693A HR P20020693 B1 HRP20020693 B1 HR P20020693B1
Authority
HR
Croatia
Prior art keywords
heavy chain
light chain
chain
peptid
cdrs
Prior art date
Application number
HR20020693A
Other languages
English (en)
Croatian (hr)
Inventor
M. Holtzman David
Demattos Ronald
R. Bales Kelly
M. Paul Steven
Tsurushita Naoya
Vasquez Maximiliano
Original Assignee
Washington University
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020693(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Washington University, Eli Lilly And Company filed Critical Washington University
Publication of HRP20020693A2 publication Critical patent/HRP20020693A2/hr
Publication of HRP20020693B1 publication Critical patent/HRP20020693B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HR20020693A 2000-02-24 2001-02-26 HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß HRP20020693B1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18460100P 2000-02-24 2000-02-24
US25449800P 2000-12-08 2000-12-08
US25446500P 2000-12-08 2000-12-08
PCT/US2001/006191 WO2001062801A2 (en) 2000-02-24 2001-02-26 Humanized antibodies that sequester amyloid beta peptide

Publications (2)

Publication Number Publication Date
HRP20020693A2 HRP20020693A2 (en) 2004-12-31
HRP20020693B1 true HRP20020693B1 (hr) 2012-01-31

Family

ID=27391859

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20020693A HRP20020693B1 (hr) 2000-02-24 2001-02-26 HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
HRP20080430AA HRP20080430B1 (hr) 2000-02-24 2001-02-26 HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID αß

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20080430AA HRP20080430B1 (hr) 2000-02-24 2001-02-26 HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID αß

Country Status (32)

Country Link
US (4) US7195761B2 (enExample)
EP (4) EP1257584B2 (enExample)
JP (2) JP4738696B2 (enExample)
KR (1) KR100767146B1 (enExample)
CN (3) CN1426423B (enExample)
AT (1) ATE279442T1 (enExample)
AU (1) AU4178601A (enExample)
BR (1) BRPI0108676B8 (enExample)
CA (1) CA2400559C (enExample)
CY (1) CY1118381T1 (enExample)
CZ (2) CZ304211B6 (enExample)
DE (2) DE1257584T1 (enExample)
DK (2) DK1481992T3 (enExample)
DZ (1) DZ3295A1 (enExample)
EA (1) EA006606B1 (enExample)
ES (2) ES2611427T3 (enExample)
HK (1) HK1048640B (enExample)
HR (2) HRP20020693B1 (enExample)
HU (2) HUP0204074A3 (enExample)
IL (3) IL151378A0 (enExample)
LT (1) LT1481992T (enExample)
MX (1) MXPA02008145A (enExample)
NO (2) NO329840B1 (enExample)
NZ (1) NZ520800A (enExample)
PL (2) PL210157B1 (enExample)
PT (2) PT1481992T (enExample)
SI (2) SI1257584T2 (enExample)
SK (2) SK288711B6 (enExample)
TR (1) TR200202799T3 (enExample)
UA (1) UA75881C2 (enExample)
WO (1) WO2001062801A2 (enExample)
ZA (1) ZA200206712B (enExample)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
EP1257584B2 (en) 2000-02-24 2013-03-06 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE60230736D1 (de) * 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
US7320790B2 (en) * 2001-04-30 2008-01-22 Eli Lilly And Company Humanized antibodies
WO2003000714A2 (en) * 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
JP4729717B2 (ja) † 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
CA2452104A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
DE60224200T2 (de) * 2001-08-17 2008-07-10 Eli Lilly And Co., Indianapolis Assayverfahren für alzheimer-krankheit
US20060073149A1 (en) * 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE419871T1 (de) * 2002-04-25 2009-01-15 Lilly Co Eli Verfahren zur behandlung von angststörungen bei älteren personen
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
FR2846667B1 (fr) * 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005010151A2 (en) 2003-06-27 2005-02-03 Abgenix, Inc Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
KR101139103B1 (ko) * 2003-09-12 2012-07-05 아피리스 아게 아페레시스 장치
US7848543B2 (en) * 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
UA93181C2 (ru) * 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
JPWO2005105998A1 (ja) * 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
US8507206B2 (en) * 2004-07-02 2013-08-13 Northwestern University Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
AU2005294131A1 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
US9907485B2 (en) * 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US9924888B2 (en) * 2004-10-15 2018-03-27 Brainlab Ag Targeted infusion of agents against parkinson's disease
US9901413B2 (en) * 2004-10-15 2018-02-27 Brainlab Ag Targeted infusion of agents for treatment of ALS
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20090074775A1 (en) * 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TW200740839A (en) 2005-06-17 2007-11-01 Wyeth Corp Methods of purifying Fc region containing proteins
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007064972A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
NO345996B1 (no) * 2005-12-12 2021-12-13 Ac Immune Sa A beta 1-42-spesifikke monoklonale antistoffer med terapeutiske egenskaper.
EP1960428B1 (en) 2005-12-12 2011-07-27 F. Hoffmann-La Roche AG Antibodies against amyloid beta with glycosylation in the variable region
KR101263294B1 (ko) * 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
SG173385A1 (en) * 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
NO348280B1 (no) * 2006-07-14 2024-11-04 Genentech Inc Humanisert antistoff
EP3988566A1 (en) * 2006-07-14 2022-04-27 AC Immune SA Humanized antibody against amyloid beta
SI2046833T1 (sl) * 2006-07-14 2013-12-31 Ac Immune S.A. Humanizirano protitelo proti amiloidu beta
HUE033466T2 (en) * 2006-10-02 2017-12-28 Ac Immune Sa Humanized antibody to beta-amyloid
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2675340C (en) 2007-01-11 2018-07-31 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
SI2842967T1 (sl) 2007-01-18 2017-01-31 Eli Lilly And Company Pegilirani amiloid beta fab
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2008104580A1 (en) 2007-03-01 2008-09-04 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP2011526240A (ja) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9265577B2 (en) 2007-05-18 2016-02-23 The Johns Hopkins University Methods and systems for providing planning and dispensation of research and/or treatment for brain disease
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
NZ599497A (en) * 2007-06-12 2013-11-29 Ac Immune Sa Humanized antibodies to amyloid beta
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
CA2704064A1 (en) * 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
WO2009048537A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MY158903A (en) * 2007-11-16 2016-11-30 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
WO2010024927A2 (en) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8614297B2 (en) * 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
CA2782250C (en) 2009-12-11 2016-08-30 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
WO2011109246A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CA3125875A1 (en) * 2011-12-22 2013-06-27 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
WO2014007982A2 (en) * 2012-07-03 2014-01-09 Janssen Alzheimer Immunotherapy C-terminal and central epitope a-beta antibodies
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2638850T3 (es) 2013-02-19 2017-10-24 Pfizer Inc. Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP4324480A3 (en) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102373930B1 (ko) 2013-09-13 2022-03-11 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
EP3129388A1 (en) 2014-04-10 2017-02-15 Pfizer Inc. 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CR20170572A (es) 2015-06-17 2018-03-20 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
WO2017032686A1 (en) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018005353A (es) 2015-10-28 2018-08-14 Univ Pennsylvania Administracion intratecal de vectores virales adenop-asociados para terapia genica.
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
DK3419979T3 (da) 2016-02-23 2020-03-23 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser
CN109641898B (zh) 2016-07-01 2022-04-08 辉瑞公司 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
AU2017299858B2 (en) 2016-07-18 2024-07-25 Promis Neurosciences, Inc. Antibodies to Amyloid beta
CN109562167A (zh) * 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
KR20190054094A (ko) 2016-09-27 2019-05-21 세로 테라퓨틱스, 인코포레이티드 키메라 포식작용 수용체 분자
US11124562B2 (en) 2016-10-28 2021-09-21 Washington University Anti-ApoE antibodies
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
BR112019018688A2 (pt) 2017-03-10 2020-04-07 Pfizer derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
WO2018163030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3066077A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
IL271290B2 (en) 2017-06-22 2023-11-01 Pfizer Dihydro-pyrrolo-pyridine derivatives
CA3067597C (en) 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
CN111386284B (zh) 2017-09-26 2024-08-30 森罗治疗公司 嵌合吞噬受体分子和使用方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
JP7497294B2 (ja) 2018-03-23 2024-06-10 ファイザー・インク ピペラジンアザスピロ誘導体
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
US20210309726A1 (en) * 2018-05-21 2021-10-07 New York University Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
EP3898667A2 (en) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
FR3091999A1 (fr) * 2019-01-25 2020-07-31 Mexbrain Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
MX2024009597A (es) 2022-02-03 2024-08-15 Lilly Co Eli Imagenologia de tau regional para diagnosticar y tratar la enfermedad de alzheimer.
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
FR2608669A1 (fr) 1986-12-19 1988-06-24 Boussois Sa Vitrage pret a sa pose et son procede de fabrication et de fixation
US4933156A (en) 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
EP1298436B1 (en) * 1992-10-26 2010-07-14 Elan Pharmaceuticals, Inc. Methods for the identification of Beta-amyloid peptide (BAP) release inhibitor compounds
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
CA2171553A1 (en) * 1993-09-28 1995-04-06 Charles A. Marotta Using antisense oligonucleotides to modulate nerve growth and to reverse .beta./a4 amyloid-induced morphology
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2001512689A (ja) * 1997-08-11 2001-08-28 カイロン コーポレイション Ｔ細胞を遺伝子改変するための方法
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ES2345746T3 (es) 1998-05-21 2010-09-30 University Of Tennessee Research Foundation Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
WO2001010900A2 (en) 1999-08-04 2001-02-15 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
DE60044057D1 (de) 1999-09-03 2010-05-06 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
EP1257584B2 (en) 2000-02-24 2013-03-06 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DK1317479T3 (da) 2000-09-06 2009-11-23 Aventis Pharma Sa Fremgangsmåder og sammensætninger for sygdomme, der er associeret med amyloidosis
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE60224200T2 (de) 2001-08-17 2008-07-10 Eli Lilly And Co., Indianapolis Assayverfahren für alzheimer-krankheit

Also Published As

Publication number Publication date
US20110158986A1 (en) 2011-06-30
CA2400559A1 (en) 2001-08-30
ES2184660T3 (es) 2005-05-01
EP1257584B1 (en) 2004-10-13
US20060039906A1 (en) 2006-02-23
DE60106394D1 (de) 2004-11-18
CN101670105B (zh) 2014-08-06
IL193631A0 (en) 2009-02-11
CZ2008595A3 (cs) 2017-05-03
CN1426423B (zh) 2010-05-12
EA006606B1 (ru) 2006-02-24
PL356798A1 (en) 2004-07-12
PT1257584E (pt) 2005-01-31
BRPI0108676B1 (pt) 2015-09-15
NZ520800A (en) 2004-04-30
WO2001062801A2 (en) 2001-08-30
KR100767146B1 (ko) 2007-10-15
LT1481992T (lt) 2017-02-10
EP3070100B1 (en) 2021-07-07
EP3070100A1 (en) 2016-09-21
HRP20080430B1 (hr) 2016-12-16
SK12212002A3 (sk) 2003-10-07
PL210157B1 (pl) 2011-12-30
NO20023957L (no) 2002-10-22
CA2400559C (en) 2012-05-01
CN1426423A (zh) 2003-06-25
CZ20022851A3 (cs) 2003-09-17
WO2001062801A3 (en) 2002-01-31
IL193631A (en) 2010-11-30
ES2184660T5 (es) 2013-05-09
ZA200206712B (en) 2003-11-21
HRP20020693A2 (en) 2004-12-31
EP1481992A2 (en) 2004-12-01
PT1481992T (pt) 2017-01-02
MXPA02008145A (es) 2004-04-05
KR20020089359A (ko) 2002-11-29
UA75881C2 (en) 2006-06-15
EP1257584B9 (en) 2004-12-01
US8591894B2 (en) 2013-11-26
JP2003523764A (ja) 2003-08-12
CN101670105A (zh) 2010-03-17
PL218883B1 (pl) 2015-02-27
NO337363B1 (no) 2016-03-29
IL151378A (en) 2010-04-29
CZ304211B6 (cs) 2014-01-08
HRP20080430A2 (en) 2008-11-30
BR0108676A (pt) 2003-01-07
US7195761B2 (en) 2007-03-27
CN104341500A (zh) 2015-02-11
JP4914412B2 (ja) 2012-04-11
DK1481992T3 (en) 2017-01-30
JP2009046497A (ja) 2009-03-05
HU230768B1 (hu) 2018-03-28
SI1257584T2 (sl) 2013-07-31
EP1481992A3 (en) 2004-12-08
SI1257584T1 (en) 2005-04-30
HK1048640B (en) 2005-04-01
HRP20080430A9 (en) 2009-02-28
NO20023957D0 (no) 2002-08-20
DK1257584T4 (da) 2013-03-25
DE60106394T2 (de) 2006-03-09
EP3150633A1 (en) 2017-04-05
US20040043418A1 (en) 2004-03-04
EP1257584A2 (en) 2002-11-20
HUP0204074A3 (en) 2004-07-28
ATE279442T1 (de) 2004-10-15
CZ306683B6 (cs) 2017-05-03
EP1481992B1 (en) 2016-11-02
DK1257584T3 (da) 2005-01-17
SK288711B6 (sk) 2019-11-05
TR200202799T3 (tr) 2003-03-21
ES2611427T3 (es) 2017-05-08
DE60106394T3 (de) 2013-07-25
HUP0204074A2 (hu) 2003-03-28
SI1481992T1 (sl) 2017-01-31
US7892545B2 (en) 2011-02-22
IL151378A0 (en) 2003-04-10
EP1257584B2 (en) 2013-03-06
BRPI0108676B8 (pt) 2021-05-25
NO20083805L (no) 2002-10-22
AU4178601A (en) 2001-09-03
DE1257584T1 (de) 2003-05-28
HK1048640A1 (en) 2003-04-11
SK288723B6 (sk) 2020-01-07
ES2184660T1 (es) 2003-04-16
HUP0800571A2 (en) 2003-03-28
US20090238821A1 (en) 2009-09-24
NO329840B1 (no) 2011-01-10
DZ3295A1 (fr) 2001-08-30
JP4738696B2 (ja) 2011-08-03
CY1118381T1 (el) 2017-06-28
EA200200897A1 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
AR035581A1 (es) Anticuerpos para il-1beta humana
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
BR0207151A (pt) Moléculas de aglutinação terapêuticas
GEP20074222B (en) Antibodies to cd40
TW200716182A (en) Antibodies directed to CD20 and uses thereof
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
PE20030104A1 (es) Anticuerpos humanos para cd154
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ547157A (en) Interferon Alpha Antibodies and their uses
SG156547A1 (en) Human monoclonal antibodies to ctla-4
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
HRP20110758T1 (en) Il-17 antagonistic antibodies
HRP20030089B1 (hr) Anti-tnf protutijela, pripravci, postupci i primjena
NZ593068A (en) IL-18 antibody
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190129

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200204

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20210226